ストックスクリーナーアプリを入手
0.95
5.04%
0.0456
プレマーケット:
.95
前日終値:
$0.9044
開ける：
$0.92
24時間の取引高:
139.62K
Relative Volume:
0.25
時価総額：
$34.82M
収益：
-
当期純損益:
$-9.16M
株価収益率:
-1.6667
EPS:
-0.57
ネットキャッシュフロー:
$-8.75M
1週間 パフォーマンス:
+7.20%
1か月 パフォーマンス:
-6.86%
6か月 パフォーマンス:
-31.65%
1年 パフォーマンス:
-20.17%
1日の値動き範囲:
$0.91
$0.9596
1週間の範囲:
$0.81
$0.9596
52週間の値動き範囲:
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
名前
Renovorx Inc
セクター
電話
408-800-2649
住所
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.95 | 33.15M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc (RNXT) 最新ニュース
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Cipla Limited (CIPLA) Gets Regulatory ApprovalFinancial Sector Performance & Stay One Step Ahead of Risk Events - earlytimes.in
Is RenovoRx Inc. stock positioned for long term growthRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Is RenovoRx Inc. stock a top pick in earnings seasonWeekly Profit Report & Community Driven Trade Alerts - newser.com
RenovoRx Expands Reach with RenovoCath Approval - MSN
Is RenovoRx Inc. stock dividend yield sustainablePortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-19 17:29:20 - newser.com
Tick level data insight on RenovoRx Inc. volatility2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - Investing News Network
RenovoRx CEO Shaun Bagai to Present at Alliance Global Partners Virtual Showcase on Oncology Innovations - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Share RenovoCath, $900K YTD Revenue at AGP Showcase - Stock Titan
What drives RenovoRx Inc stock pricePrice Gap Trading Strategies & Go Beyond the Headlines With Analyst Picks - earlytimes.in
Does RenovoRx Inc. fit your quant trading modelJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
RenovoRx : Corporate Overview - MarketScreener
Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx - TipRanks
Can RenovoRx Inc. stock deliver consistent earnings growthJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
RenovoRx launches public stock offering - MSN
Is RenovoRx Inc. stock supported by innovation pipelineBull Run & Free Safe Entry Trade Signal Reports - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
RenovoRx Earnings Call: Positive Momentum and Strategic Growth - MSN
RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating - TipRanks
RenovoRx price target lowered to $3 from $3.50 at Alliance Global - MSN
What analyst consensus says on RenovoRx Inc. stockWeekly Investment Recap & Smart Swing Trading Alerts - newser.com
RenovoRx Enters Capital on Demand Sales Agreement - TipRanks
[8-K] RenovoRx, Inc. Reports Material Event | RNXT SEC FilingForm 8-K - Stock Titan
RenovoRx may offer securities for up to $50 millionSEC filing - MarketScreener
Renovorx Inc (RNXT) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):